Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 18,750 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 18,750 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $56.51, for a total value of $1,059,562.50. Following the transaction, the insider now directly owns 170,237 shares of the company’s stock, valued at $9,620,092.87. This represents a 9.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Monday, January 27th, Timothy Rolph sold 31,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.77, for a total value of $1,742,812.50.
• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total transaction of $148,924.38.

Akero Therapeutics Price Performance

NASDAQ:AKRO opened at $54.21 on Friday. Akero Therapeutics, Inc. has a 12-month low of $17.84 and a 12-month high of $58.40. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -14.46 and a beta of -0.11. The stock’s 50 day moving average price is $32.60 and its two-hundred day moving average price is $29.85. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. UBS Group increased their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Canaccord Genuity Group lifted their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. HC Wainwright increased their price target on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, Morgan Stanley upped their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AKRO. AlphaQuest LLC boosted its holdings in shares of Akero Therapeutics by 32,588.0% during the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock worth $227,000 after buying an additional 8,147 shares during the period. Proficio Capital Partners LLC acquired a new stake in Akero Therapeutics during the fourth quarter worth approximately $320,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Akero Therapeutics by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock worth $15,042,000 after acquiring an additional 8,096 shares during the period. Handelsbanken Fonder AB grew its position in shares of Akero Therapeutics by 5.0% in the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock valued at $584,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Akero Therapeutics by 1.3% during the fourth quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock worth $2,940,000 after purchasing an additional 1,310 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.